By a News Reporter-Staff News Editor at Drug Week -- New research on Proteobacteria is the subject of a report. According to news reporting from Bronx, New York, by NewsRx journalists, research stated, "Pseudomonas aeruginosa is a community-acquired, nosocomial pathogen that is an important cause of human morbidity and mortality; it is intrinsically resistant to several antibiotics and is capable of developing resistance to newly developed drugs via a variety of mechanisms. P aeruginosa's ubiquity and multidrug resistance (MDR) warrants the development of innovative methods that overcome its ability to develop resistance."
The news correspondents obtained a quote from the research from the Department of Medicine, "We have previously described a nitric oxide-releasing nanoparticle (NO-np) platform that effectively kills gram-positive and gram-negative organisms in vitro and accelerates clinical recovery in vivo in murine wound and abscess infection models. We have also demonstrated that when glutathione (GSH) is added to NO-np, the nitroso intermediate S-nitrosoglutathione (GSNO) is formed, which has greater activity against P aeruginosa and other gram-negative organisms compared with NO-np alone. In the current study, we evaluate the potential of NO-np to generate GSNO both in vitro and in vivo in a murine excisional wound model infected with an MDR clinical isolate of P aeruginosa. Whereas NO-np alone inhibited P aeruginosa growth in vitro for up to 8 hours, NO-np+GSH completely inhibited P aeruginosa growth for 24 hours. Percent survival in the NO-np+GSH-treated isolates was significantly lower than in the NO-np (36.1% vs 8.3%; p=.004). In addition, NO-np+GSH accelerated wound closure in P aeruginosa-infected wounds, and NO-np+GSH-treated wounds had significantly lower bacterial burden when compared to NO-np-treated wounds (p <.001)."
According to the news reporters, the research concluded: "GSNO is easily generated from our NO-np platform and has the potential to be used as an antimicrobial agent against MDR organisms such as P aeruginosa."
For more information on this research see: Nitrosoglutathione generating nitric oxide nanoparticles as an improved strategy for combating Pseudomonas aeruginosa-infected wounds. Journal of Drugs In Dermatology, 2012;11(12):1471-7 (see also Proteobacteria).
Our news journalists report that additional information may be obtained by contacting J. Chouake, Dept. of Medicine, Division of Dermatology, Montefiore Medical Center, Bronx, NY, United States. Additional authors for this research include D. Schairer, A. Kutner, D.A. Sanchez, J. Makdisi, K. Blecher-Paz, P. Nacharaju, C. Tuckman-Vernon, P. Gialanella, J.M. Friedman, J.D. Nosanchuk and A.J Friedman.
Keywords for this news article include: Pharmaceuticals, Bronx, Drugs, Therapy, New York, Chemicals, Chemistry, Nanoparticle, Nitric Oxide, United States, Nanotechnology, Nitrogen Oxides, Pseudomonadaceae, Gammaproteobacteria, Emerging Technologies, Pseudomonas Infections, Pseudomonas aeruginosa, North and Central America, Reactive Nitrogen Species.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC